 |
| |
| Sep-26-19 | Upgrade |
Citigroup |
Neutral → Buy |
$87 → $90 |
|
| Aug-20-19 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
$80 |
|
| Jun-27-19 | Upgrade |
Wolfe Research |
Underperform → Peer Perform |
|
|
| Jun-26-19 | Upgrade |
SVB Leerink |
Mkt Perform → Outperform |
$88 |
|
| May-28-19 | Initiated |
Goldman |
Neutral |
|
|
| Apr-29-19 | Upgrade |
BMO Capital Markets |
Underperform → Market Perform |
|
|
| Mar-25-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| Jan-23-19 | Initiated |
UBS |
Neutral |
$91 |
|
| Jan-03-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Dec-26-18 | Initiated |
Standpoint Research |
Buy |
|
|
| Oct-22-18 | Reiterated |
SunTrust |
Buy |
$157 → $135 |
|
| Oct-04-18 | Reiterated |
BofA/Merrill |
Buy |
$107 → $106 |
|
| Jun-01-18 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| May-30-18 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Jan-30-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$99 → $131 |
|
| Jan-29-18 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Oct-30-17 | Reiterated |
Leerink Partners |
Outperform |
$108 → $107 |
|
| Oct-02-17 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Sep-25-17 | Downgrade |
UBS |
Buy → Neutral |
$79 → $92 |
|
| Aug-17-17 | Initiated |
Evercore ISI |
Outperform |
$95 |
|
|
|
| Dec-08-19 07:30AM | New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PR Newswire |
| Dec-07-19 09:00AM | More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen PR Newswire |
| 07:33AM | Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL) PR Newswire |
| 07:30AM | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) PR Newswire |
| Dec-06-19 04:30PM | Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting GlobeNewswire |
| 07:27AM | Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial Reuters |
| 06:00AM | AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis CNW Group |
| Dec-05-19 10:57AM | Merck Stock Is On An Upswing In 2019 Should You Buy This Pharma Stock? Investor's Business Daily |
| 09:07AM | J&J Stock Witnesses Volatility in '19: What to Expect in 2020 Zacks |
| Dec-04-19 10:00AM | AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily |
| Dec-03-19 09:26AM | Where to Buy Booming Biotech ETFs Investopedia |
| 05:06AM | [video]AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug TheStreet.com |
| Dec-02-19 05:45PM | AbbVie (ABBV) Stock Moves -0.79%: What You Should Know Zacks |
| 02:29PM | Disney Stock Is Loved by Wall Street. Its Bonds? Not So Much. Barrons.com |
| 09:18AM | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019 Zacks |
| Dec-01-19 09:30AM | AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue? Zacks |
| Nov-30-19 05:14PM | Did Hedge Funds Drop The Ball On AbbVie Inc (ABBV) ? Insider Monkey |
| Nov-29-19 09:15AM | Market Serves Up More Records for Thanksgiving Zacks |
| Nov-28-19 07:00AM | The 3 Worst-Performing Health Care Stocks of 2019 So Far Barrons.com |
| Nov-27-19 11:22PM | Why some corporate bond investors see higher risk in higher ratings Financial Times |
| 07:06PM | 3 Stocks for Value Investors to Buy as Market Reaches New High Zacks |
| 12:33PM | Johnson Adviser Warns of Chance of Hung Parliament: U.K. Votes Bloomberg |
| 11:02AM | Tory Prime Minister Johnson has held secret talks with U.S. about privatizing National Health Service, Labour rival claims MarketWatch |
| Nov-26-19 05:54PM | BeiGene Shares Climb Nearly 50% After Amgen Deal GuruFocus.com |
| 12:43PM | Best Dividend Stocks for December 2019 Investopedia |
| 09:20AM | 3 Top Dividend Stocks to Maximize Your Retirement Income - November 26, 2019 Zacks |
| Nov-25-19 08:56AM | Timing the Market, Is it Possible? - November 25, 2019 Zacks |
| Nov-22-19 11:31AM | Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes Zacks |
| 10:08AM | AstraZeneca shares rise on early U.S. approval for leukemia drug Reuters |
| Nov-21-19 08:30AM | AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting PR Newswire |
| 04:00AM | Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration GlobeNewswire |
| Nov-20-19 09:55AM | Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019 Zacks |
| 09:22AM | Myovant Up on Successful Completion of Prostate Cancer Study Zacks |
| 08:00AM | Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology CNW Group |
| 07:58AM | 5 Corporate Giants That Popped After Latest Earnings Release Zacks |
| Nov-19-19 10:33AM | Drug Legislation Likely to Dry Up Biotech Funding GuruFocus.com |
| 10:23AM | Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira Zacks |
| 05:00AM | AbbVie- On the Cutting Edge MoneyShow |
| Nov-18-19 08:00AM | AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes PR Newswire |
| Nov-17-19 03:40PM | AbbVie's Humira on Pace to Become Biggest Seller by 2024 GuruFocus.com |
| Nov-15-19 07:12AM | Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates Zacks |
| 06:41AM | 4 Big Drugmakers to Bet on After a Great Earnings Season Zacks |
| Nov-14-19 11:00PM | Credit market fears of downgrades have not materialised Financial Times |
| 06:24PM | Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter GuruFocus.com |
| 08:28AM | Exicures shares up on Allergan partnership MarketWatch |
| 06:00AM | Beware of Runs on Bond Funds Barrons.com |
| 05:01AM | AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know Barrons.com |
| Nov-13-19 02:34PM | Should Investors Add Johnson & Johnson Stock to Their Shopping Lists? InvestorPlace |
| 12:03PM | AbbVie Takes on Debt to Buy Allergan GuruFocus.com |
| 10:46AM | AbbVies $30 Billion Bond Sale Was Wall Streets Biggest This Year Barrons.com |
| 09:30AM | Abbott Labs Chooses an Insider to Be Its New CEO Barrons.com |
| 03:52AM | Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon TheStreet.com |
| Nov-12-19 09:45PM | AbbVie Prices $30 Billion of Senior Unsecured Notes PR Newswire |
| 05:12PM | AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition Bloomberg |
| 04:40PM | US Indexes End the Day Higher Tuesday GuruFocus.com |
| 02:11PM | Corporations Pile Into Bond Market as Borrowing Costs Drop Bloomberg |
| 11:15AM | New Positive Data for RINVOQ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting PR Newswire |
| 08:31AM | The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv Zacks |
| 06:56AM | AbbVie Rises 3% Investing.com |
| 06:46AM | AbbVie sells $30bn of bonds to finance Allergan takeover Financial Times |
| 05:00AM | AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report TheStreet.com |
| Nov-11-19 01:50PM | Top Research Reports for Toyota, Netflix & AbbVie Zacks |
| 01:12PM | Mario Gabelli Continues to Buy AbbVie, Axalta GuruFocus.com |
| 09:03AM | AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL Zacks |
| Nov-08-19 09:00AM | Psst! Want the Secret to Picking Winning Stocks? Keep Reading. Barrons.com |
| 08:45AM | 10 Medical Marijuana Stocks to Cure Your Portfolio InvestorPlace |
| 07:30AM | AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia PR Newswire |
| 05:50AM | AbbVie Rises 3% Investing.com |
| Nov-07-19 08:41PM | AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes PR Newswire |
| 10:49AM | Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb Zacks |
| 10:18AM | AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's new sr. notes; stable outlook Moody's |
| Nov-06-19 03:06PM | AbbVie Announces Launch of Private Offering of Senior Unsecured Notes PR Newswire |
| 05:11AM | Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Cheque? Simply Wall St. |
| Nov-05-19 06:16PM | Vanguard Health Care Fund Sells Out of Allergan GuruFocus.com |
| 11:02AM | Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View Zacks |
| 10:48AM | Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track Benzinga |
| 10:11AM | The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb Zacks |
| 04:40AM | [video]Allergan Tops Q3 Earnings, Bumps 2019 Sales Guidance Amid AbbVie Takeover TheStreet.com |
| Nov-04-19 01:00PM | Value Biotech ETFs & Stocks to Buy Now Zacks |
| 11:54AM | ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally Zacks |
| 11:20AM | Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks GuruFocus.com |
| 10:08AM | Top Ranked Income Stocks to Buy for November 4th Zacks |
| 09:10AM | Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y Zacks |
| 09:08AM | Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss Zacks |
| 09:07AM | 5 High-Flying Stocks Near 52-Week High That Can Scale Higher Zacks |
| 08:44AM | When Does Market Timing Actually Work? - November 04, 2019 Zacks |
| 08:31AM | AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting PR Newswire |
| 01:00AM | Rounding Up Big Pharma Earnings Morningstar |
| Nov-03-19 09:47PM | Edited Transcript of ABBV earnings conference call or presentation 1-Nov-19 1:00pm GMT Thomson Reuters StreetEvents |
| Nov-02-19 11:56AM | Barron's Picks And Pans: AbbVie, Alibaba, Fiat Chrysler, Garmin And More Benzinga |
| 07:00AM | Starbucks, AbbVie, and 4 Others Announce Dividend Hikes Barrons.com |
| Nov-01-19 07:02PM | 5 High-Yield Stocks That Can Keep On Giving Barrons.com |
| 04:21PM | AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms Investor's Business Daily |
| 04:21PM | S&P500 and Nasdaq hit new records after October jobs numbers beat expectations MarketWatch |
| 03:24PM | 6 Top Stock Trades for Monday: BABA, PINS, CVX InvestorPlace |
| 02:47PM | AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View Zacks |
| 11:28AM | AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms Investor's Business Daily |
| 11:07AM | WIll Allergan (AGN) Beat Estimates This Earnings Season? Zacks |
| 10:55AM | Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates Zacks |
| 10:10AM | AbbVie says multiple parties vying for assets related to Allergan deal approval Reuters |
|
|
|
|
| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; and Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Sep 27 | Sale | 75.02 | 15,515 | 1,163,873 | 0 | Oct 01 05:52 PM | | Schumacher Laura J | Vice Chairman | Sep 16 | Buy | 70.42 | 25,000 | 1,760,523 | 164,838 | Sep 18 04:25 PM | | Donoghoe Nicholas | SVP, Enterprise Innovation | Aug 29 | Buy | 66.19 | 7,525 | 498,057 | 13,090 | Aug 30 04:08 PM | | Stewart Jeffrey Ryan | SVP, US Commercial Operations | Aug 16 | Buy | 64.44 | 15,552 | 1,002,169 | 65,304 | Aug 20 04:16 PM | | AUSTIN ROXANNE S | Director | Aug 01 | Buy | 65.66 | 25,000 | 1,641,400 | 117,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 31 | Buy | 66.02 | 30,000 | 1,980,690 | 92,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 30 | Buy | 66.35 | 10,000 | 663,500 | 62,114 | Jul 31 04:46 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Jul 29 | Buy | 67.28 | 30,000 | 2,018,385 | 75,763 | Jul 31 04:46 PM | | AUSTIN ROXANNE S | Director | Jun 26 | Buy | 67.50 | 11,500 | 776,250 | 52,114 | Jun 28 04:47 PM | | CHASE WILLIAM J | EVP, Finance & Administration | Jun 26 | Buy | 67.30 | 30,400 | 2,045,920 | 169,552 | Jun 28 04:47 PM | | RAPP EDWARD J | Director | Jun 26 | Buy | 67.30 | 7,500 | 504,750 | 30,662 | Jun 28 04:48 PM | | Durkin Brian L | VP, Controller | Mar 25 | Sale | 79.69 | 475 | 37,853 | 9,121 | Mar 25 04:34 PM | | Schumacher Laura J | Vice Chairman | Mar 14 | Sale | 80.00 | 25,000 | 2,000,000 | 139,838 | Mar 15 05:53 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | Mar 05 | Sale | 79.03 | 15,797 | 1,248,480 | 93,312 | Mar 06 05:03 PM | | Schumacher Laura J | Vice Chairman | Dec 28 | Sale | 90.00 | 25,000 | 2,250,000 | 134,322 | Jan 02 04:49 PM | | CHASE WILLIAM J | EVP, Finance & Administration | Dec 12 | Sale | 90.00 | 60,000 | 5,400,000 | 104,863 | Dec 14 05:12 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Dec 11 | Sale | 88.75 | 16,850 | 1,495,438 | 286,203 | Dec 13 04:56 PM |
|
|
|
|
|
|
